Julia serves as General Counsel for Microbial Machines, Courage Therapeutics and NextRNA Therapeutics. She is responsible for corporate formation, founder and seed round financing, technology licensing, contracting and general company administration. Earlier in her career, Julia was a litigator, primarily in the areas of government contracts and consumer financial services. She earned her J.D. from the Georgetown University Law Center and graduated magna cum laude from Connecticut College.

Stephanie is a biotechnology and medical device consultant and investor. She is also a Partner and Analyst at Ascentia Asset Management, a biotech private investment fund. Stephanie was previously a reconstructive plastic surgeon and former Assistant Professor in the Department of Surgery at Yale University School of Medicine. She received her M.D. from Albert Einstein College of Medicine.

Jun has a multidisciplinary background and deep expertise in CAR T cell therapy, immuno-oncology, and tumor microenvironment. Prior to joining Dynamic Cell Therapies, he worked at Massachusetts General Hospital and Harvard Medical School, where he developed multiple therapeutic strategies overcoming resistance to cancer immunotherapy and provided mechanistic insights in support of clinical trials. Jun received his Ph.D. from the University of Wisconsin-Madison, followed by postdoctoral training at Massachusetts General Hospital.

Prior to joining Dynamic Cell Therapies, Sakeena led in vivo pharmacology research at Ikena Oncology focusing on proof of concept and candidate selection studies targeting the hippo pathway in cancer. Throughout Sakeena’s career, she has successfully advanced several molecules into the clinic, spending over 14 years at Takeda Oncology and EMD Serono Inc. in the cancer pharmacology group.  She holds a B.A. in Biology from Oberlin College.

Carl is an Associate Professor of Medicine at the Dana-Farber Cancer Institute & Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. His original research has resulted in the founding of Dynamic Cell Therapies, Microbial Machines and Mana Therapeutics. He is the recipient of numerous awards and honors, including the W.M. Keck Distinguished Young Scholars Award, Department of Defense Idea Award, The NCI Director’s Provocative Questions Award, the National Science Foundation Collaborative Research Project Award and the NIH Director’s Pioneer Award. Carl received his M.D. from Columbia University Vagelos College of Physicians and Surgeons and his Ph.D. in immunology from Tufts University.

Steven is Principal at Binney Street Capital, as well as co-founder and Scientific Advisory Board member of Microbial Machines and NextRNA Therapeutics. He was a scientific consultant at QuantumCyte, Inc. while serving as a scientist at Dana-Farber Cancer Institute. Steven received his Ph.D. in immunology from Mayo Clinic.